EGFR and prostate cancer: Well-established, recurrently deregulated pathways were detected as early drivers, such as androgen signaling in prostate cancer, core mitogen-activated protein kinase (MAPK) pathway components (such as BRAF) in melanoma, and p53 and EGFR in lung cancer.